List view / Grid view
In a recent study, scientists have highlighted the possible use of South Asian medicine, specifically, Ayurvedic medicine, to treat type 2 diabetes. In this article, Drug Target Review dives into the study’s implications and what it means for the western world of drug discovery.
A new study led by the Indiana University School of Medicine showed human induced pluripotent stem cells can improve visual acuity, vascular health and other complications related to type 2 diabetes.
A recent pre-clinical study from Washington University School of Medicine showed that a new class of compounds can potentially improve multiple aspects of metabolic syndrome, including diabetes.
Scientists have developed a multi-organoid system from stem cells that can replicate the liver-islet axis in type 2 diabetes.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Researchers have revealed that the immune system of obese mice treated with TSLP released lipids through sebaceous glands.
New findings from collaborative research in the United States have identified a promising new treatment avenue for type 2 diabetes patients centring on the activity of the amino acid, GABA.
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
Drug Target Review brings you five of the most recent developments in three-dimensional (3D) bioprinting.
A key process in β-cell regeneration has been discovered by researchers who say this could lead to improved treatments for diabetes.
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
Researchers have identified microbes that could affect the way a person metabolises glucose and lipids, leading to a potential treatment for type 2 diabetes.
